The	O 0 3
manifestations	O 4 18
of	O 19 21
Lyme	B-KP 22 26
disease	I-KP 27 34
are	O 35 38
routinely	O 39 48
treated	O 49 56
with	O 57 61
antibiotics	B-KP 62 73
;	 O 73 74
therapy	O 75 82
hastens	O 83 90
the	O 91 94
resolution	O 95 105
and	O 106 109
largely	O 110 117
prevents	O 118 126
the	O 127 130
development	O 131 142
of	O 143 145
other	O 146 151
disease	O 152 159
manifestations	O 160 174
.	 O 174 175

The	O 176 179
classes	O 180 187
of	O 188 190
antibiotics	B-KP 191 202
that	O 203 207
have	O 208 212
shown	O 213 218
the	O 219 222
greatest	O 223 231
effectiveness	O 232 245
against	O 246 253
Borrelia	B-KP 254 262
spirochetes	I-KP 263 274
is	O 275 277
b-lactams	B-KP 278 287
(	 O 288 289
in	O 289 291
particular	O 292 302
cephalosporins	O 303 317
)	 O 317 318
tetracyclines	B-KP 319 332
and	O 333 336
,	 O 336 337
to	O 338 340
a	O 341 342
lesser	O 343 349
extent	O 350 356
,	 O 356 357
macrolides	B-KP 358 368
.	 O 368 369

The	O 370 373
best	O 374 378
treatment	O 379 388
approach	O 389 397
,	 O 397 398
in	O 399 401
particular	O 402 412
the	O 413 416
duration	O 417 425
of	O 426 428
therapy	O 429 436
,	 O 436 437
is	O 438 440
a	O 441 442
matter	O 443 449
of	O 450 452
ongoing	O 453 460
debate	O 461 467
.	 O 467 468

It	O 469 471
is	O 472 474
quite	O 475 480
evident	O 481 488
that	O 489 493
not	O 494 497
all	O 498 501
patients	O 502 510
,	 O 510 511
and	O 512 515
most	O 516 520
certainly	O 521 530
not	O 531 534
all	O 535 538
species	O 539 546
or	O 547 549
strains	O 550 557
of	O 558 560
Borrelia	B-KP 561 569
[	 O 570 571
113	O 571 574
]	 O 574 575
respond	O 576 583
equally	O 584 591
to	O 592 594
the	O 595 598
antibiotics	B-KP 599 610
most	O 611 615
commonly	O 616 624
used	O 625 629
in	O 630 632
the	O 633 636
treatment	O 637 646
of	O 647 649
Lyme	B-KP 650 654
disease	I-KP 655 662
.	 O 662 663

Based	O 664 669
on	O 670 672
the	O 673 676
available	O 677 686
evidence	O 687 695
from	O 696 700
randomized	B-KP 701 711
controlled	I-KP 712 722
trials	I-KP 723 729
(	 O 730 731
RCTs	B-KP 731 735
)	 O 735 736
,	 O 736 737
treatment	O 738 747
recommendations	O 748 763
have	O 764 768
been	O 769 773
published	O 774 783
by	O 784 786
the	O 787 790
Infectious	O 791 801
Diseases	O 802 810
Society	O 811 818
of	O 819 821
America	O 822 829
(	 O 830 831
IDSA	O 831 835
)	 O 835 836
[	 O 837 838
221	O 838 841
]	 O 841 842
,	 O 842 843
the	O 844 847
American	O 848 856
Academy	O 857 864
of	O 865 867
Pediatrics	O 868 878
[	 O 879 880
271	O 880 883
]	 O 883 884
,	 O 884 885
and	O 886 889
by	O 890 892
a	O 893 894
variety	O 895 902
of	O 903 905
national	O 906 914
and	O 915 918
supranational	O 919 932
associations	O 933 945
in	O 946 948
Europe	O 949 955
[203,272]	O 956 965
(www.eucalb.com).	O 966 983

As	O 984 986
the	O 987 990
comparison	O 991 1001
between	O 1002 1009
the	O 1010 1013
guidelines	O 1014 1024
published	O 1025 1034
by	O 1035 1037
the	O 1038 1041
IDSA	O 1042 1046
and	O 1047 1050
the	O 1051 1054
EUCALB	O 1055 1061
in	O 1062 1064
Table	O 1065 1070
4	O 1071 1072
illustrates	O 1073 1084
,	 O 1084 1085
the	O 1086 1089
approaches	O 1090 1100
to	O 1101 1103
therapy	O 1104 1111
are	O 1112 1115
largely	O 1116 1123
similar	O 1124 1131
on	O 1132 1134
both	O 1135 1139
sides	O 1140 1145
of	O 1146 1148
the	O 1149 1152
Atlantic	O 1153 1161
,	 O 1161 1162
but	O 1163 1166
there	O 1167 1172
are	O 1173 1176
some	O 1177 1181
minor	O 1182 1187
differences	O 1188 1199
in	O 1200 1202
the	O 1203 1206
recommended	O 1207 1218
dosage	O 1219 1225
and	O 1226 1229
treatment	O 1230 1239
duration	O 1240 1248
.	 O 1248 1249

Note	O 1250 1254
that	O 1255 1259
the	O 1260 1263
International	O 1264 1277
Lyme	O 1278 1282
and	O 1283 1286
Associated	O 1287 1297
Diseases	O 1298 1306
Society	O 1307 1314
has	O 1315 1318
also	O 1319 1323
published	O 1324 1333
guidelines	O 1334 1344
for	O 1345 1348
the	O 1349 1352
management	O 1353 1363
of	O 1364 1366
Lyme	B-KP 1367 1371
disease	I-KP 1372 1379
[	 O 1380 1381
273	O 1381 1384
]	 O 1384 1385
.	 O 1385 1386

These	O 1387 1392
advocate	O 1393 1401
more	O 1402 1406
aggressive	O 1407 1417
and	O 1418 1421
longer	O 1422 1428
treatment	O 1429 1438
courses	O 1439 1446
for	O 1447 1450
patients	O 1451 1459
with	O 1460 1464
persistent	O 1465 1475
symptoms	O 1476 1484
or	O 1485 1487
refractory	O 1488 1498
disease	O 1499 1506
,	 O 1506 1507
but	O 1508 1511
much	O 1512 1516
of	O 1517 1519
the	O 1520 1523
terminology	O 1524 1535
is	O 1536 1538
poorly	O 1539 1545
defined	O 1546 1553
and	O 1554 1557
the	O 1558 1561
cited	O 1562 1567
“	 O 1568 1569
evidence	O 1569 1577
”	 O 1577 1578
is	O 1579 1581
largely	O 1582 1589
restricted	O 1590 1600
to	O 1601 1603
older	O 1604 1609
studies	O 1610 1617
that	O 1618 1622
support	O 1623 1630
such	O 1631 1635
an	O 1636 1638
approach	O 1639 1647
and	O 1648 1651
ignores	O 1652 1659
much	O 1660 1664
of	O 1665 1667
the	O 1668 1671
other	O 1672 1677
available	O 1678 1687
evidence	O 1688 1696
.	 O 1696 1697

The	O 1698 1701
results	O 1702 1709
of	O 1710 1712
several	O 1713 1720
RCTs	B-KP 1721 1725
and	O 1726 1729
a	O 1730 1731
large	O 1732 1737
retrospective	O 1738 1751
study	O 1752 1757
do	O 1758 1760
not	O 1761 1764
show	O 1765 1769
any	O 1770 1773
benefit	O 1774 1781
in	O 1782 1784
extending	O 1785 1794
the	O 1795 1798
duration	O 1799 1807
of	O 1808 1810
treatment	O 1811 1820
with	O 1821 1825
doxycycline	B-KP 1826 1837
from	O 1838 1842
10	O 1843 1845
days	O 1846 1850
to	O 1851 1853
15	O 1854 1856
or	O 1857 1859
20	O 1860 1862
days	O 1863 1867
in	O 1868 1870
patients	O 1871 1879
with	O 1880 1884
EM	B-KP 1885 1887
[	 O 1888 1889
274-276	O 1889 1896
]	 O 1896 1897
.	 O 1897 1898

Retrospectively	O 1899 1914
obtained	O 1915 1923
data	O 1924 1928
suggest	O 1929 1936
a	O 1937 1938
similar	O 1939 1946
conclusion	O 1947 1957
for	O 1958 1961
amoxicillin	B-KP 1962 1973
[	 O 1974 1975
276	O 1975 1978
]	 O 1978 1979
.	 O 1979 1980

In	O 1981 1983
another	O 1984 1991
double-blind	O 1992 2004
RCT	B-KP 2005 2008
,	 O 2008 2009
treatment	O 2010 2019
of	O 2020 2022
patients	O 2023 2031
with	O 2032 2036
disseminated	O 2037 2049
Lyme	B-KP 2050 2054
borreliosis	I-KP 2055 2066
with	O 2067 2071
a	O 2072 2073
3-week	O 2074 2080
course	O 2081 2087
of	O 2088 2090
i.v.	O 2091 2095

ceftriaxone	O 2096 2107
followed	O 2108 2116
by	O 2117 2119
100	O 2120 2123
days	O 2124 2128
of	O 2129 2131
amoxicillin	B-KP 2132 2143
did	O 2144 2147
not	O 2148 2151
improve	O 2152 2159
the	O 2160 2163
outcome	O 2164 2171
compared	O 2172 2180
to	O 2181 2183
a	O 2184 2185
3-week	O 2186 2192
course	O 2193 2199
of	O 2200 2202
ceftriaxone	B-KP 2203 2214
alone	O 2215 2220
[	 O 2221 2222
277	O 2222 2225
]	 O 2225 2226
.	 O 2226 2227

These	O 2228 2233
findings	O 2234 2242
do	O 2243 2245
not	O 2246 2249
exclude	O 2250 2257
that	O 2258 2262
some	O 2263 2267
patients	O 2268 2276
may	O 2277 2280
benefit	O 2281 2288
from	O 2289 2293
longer	O 2294 2300
or	O 2301 2303
more	O 2304 2308
aggressive	O 2309 2319
therapy	O 2320 2327
,	 O 2327 2328
but	O 2329 2332
the	O 2333 2336
risk-benefit	O 2337 2349
ratio	O 2350 2355
has	O 2356 2359
to	O 2360 2362
be	O 2363 2365
carefully	O 2366 2375
weighed	O 2376 2383
for	O 2384 2387
each	O 2388 2392
individual	O 2393 2403
patient	O 2404 2411
.	 O 2411 2412

